News & Press

  • Search

May 30, 2024
Teikoku Pharma USA, Inc. Announces NMPA Approved Lidoderm® in China on May 8, 2024 

https://finance.yahoo.com/news/teikoku-pharma-usa-inc-announces-131500108.htmlTeikoku Pharma USA (TPU) announced today that the NMPA (National Medical Products Administration) has approved Lidoderm® (“lidocaine 5% patch as lidocaine cataplasms”) for the treatment of Post Herpetic Neuralgia (PHN) in China. TPU entered into…

READ
September 06, 2023
Teikoku Pharma USA announces positive topline results from Phase 2 clinical trial of TPU-006, non-opioid pain management patch in Abdominoplasty Surgery.

Teikoku Pharma USA, a global pharmaceutical company, today announced positive topline results from its Phase 2 proof of concept study of TPU-006, a 4-day dexmedetomidine transdermal patch for Post Surgical Pain. The double-blind, placebo-controlled, single-dose…

READ
June 29, 2023
President and CEO Misako Fujioka Interviewed in Newsweek International

An interview with Teikoku Seiyaku President and CEO Ms. Misako Fujioka has been published in Newsweek’s June 16th 2023 international edition.The American news magazine published the interview as part of its special report “How Japan’s…

READ
June 21, 2023
Teikoku Pharma granted FDA Fast Track Designation for TPU-006, a Novel 4-day Dexmedetomidine Transdermal System for Post Operative Pain Management

Teikoku Pharma USA, a global pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track Designation for TPU-006 in managing postoperative pain. TPU-006 is an investigational 4-day dexmedetomidine transdermal system,…

READ
March 28, 2023
Change in The Board of Directors

Teikoku Seiyaku Co., Ltd. (Headquarters: Kagawa, Japan; President and CEO: Misako Fujioka) has announced the following changes in its Executive Directors at its Board of Directors Meeting after the General Meeting of Shareholders held on…

READ
March 15, 2023
Notice of Launch of ALLYDONE® Patches 27.5 mg / ALLYDONE® Patches 55 mg in Japan as Japan’s First Donepezil Transdermal Therapeutic System

Teikoku Seiyaku Co., Ltd. (Head Office: Higashikagawa City, Kagawa, Japan) and Kowa Company, Ltd. (Head Office: Nagoya City, Aichi, Japan) have announced today that on April 14, 2023, Teikoku Seiyaku and Kowa will launch ALLYDONE®…

READ
December 23, 2022
Manufacturing and Marketing Approval Received in Japan for ALLYDONE® Patches for Treatment of Dementia Due to Alzheimer’s Disease as Japan’s First Donepezil Transdermal Therapeutic System

Teikoku Seiyaku Co., Ltd. (Head Office: Higashikagawa City, Kagawa, Japan) and Kowa Company, Ltd. (Head Office: Nagoya City, Aichi, Japan) have announced that on December 23, 2022, Teikoku Seiyaku has acquired manufacturing and marketing approval…

READ
April 21, 2022
Execution of a license agreement on an exclusive marketing right in Japan of the first donepezil transdermal therapeutic system in Japan

Teikoku Seiyaku Co., Ltd. (Head office: Higashikagawa City, Kagawa, Japan) and Kowa Company, Ltd. (Head office: Nagoya City, Aichi, Japan) have reached a license agreement on an exclusive marketing right in Japan of the first…

READ
July 03, 2020
TEIKOKU SEIYAKU was selected as A Global Niche Top Company by METI in FY2020.

Teikoku Seiyaku Co., Ltd. (Headquarters: Kagawa, Japan (President and CEO: Misako Fujioka) was selected as one of the ‘Global Niche Top Companies Selection 100 in FY 2020’ by The Ministry of Economy, Trade and Industry…

READ

CONTACT US

Contact us for distribution or licensing opportunities, or to learn more about our growing portfolio of life-changing drug therapies.

"*" indicates required fields

Policy*